You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 5, 2024

Ibrexafungerp citrate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for ibrexafungerp citrate and what is the scope of freedom to operate?

Ibrexafungerp citrate is the generic ingredient in one branded drug marketed by Scynexis and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ibrexafungerp citrate has fifty patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for ibrexafungerp citrate
International Patents:50
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:ibrexafungerp citrate at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ibrexafungerp citrate
Generic Entry Date for ibrexafungerp citrate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ibrexafungerp citrate

US Patents and Regulatory Information for ibrexafungerp citrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ibrexafungerp citrate

Country Patent Number Title Estimated Expiration
Canada 2731941 AGENTS ANTIFONGIQUES (ANTIFUNGAL AGENTS) ⤷  Try a Trial
Croatia P20221414 ⤷  Try a Trial
Eurasian Patent Organization 202090445 ПРОТИВОГРИБКОВЫЕ СРЕДСТВА С ПОВЫШЕННОЙ АКТИВНОСТЬЮ ПРИ КИСЛОМ pH ⤷  Try a Trial
Japan 2020529999 酸性pHで活性の増強を示す抗真菌剤 ⤷  Try a Trial
Taiwan I805600 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.